Nextcure, INC Form 4 insider transactions

Simcere Zaiming, Inc. and 5 others reported changes in beneficial ownership of NextCure, Inc. common stock on August 10, 2026.

Avere Therapeutics announces a $500 million private placement to advance its oral IL-23 therapy AVR-001, alongside a pending merger with NextCure, aiming to fully fund operations into 2029.

Avere Therapeutics, in conjunction with NextCure, has published corporate presentation detailing the development of AVR-001, a once-weekly oral IL-23 receptor antagonist for inflammatory diseases.

ADAR1 Capital Management, LLC and 1 other reported changes in beneficial ownership of NextCure, Inc. common stock on July 30, 2026.

ADAR1 Capital Management, LLC and 1 other reported changes in beneficial ownership of NextCure, Inc. common stock on July 27, 2026.

NextCure and Avere Therapeutics have entered into a merger agreement to combine, with Avere's lead drug candidate AVR-001 for inflammatory diseases as a key focus.

NextCure and Avere Therapeutics have entered into a definitive merger agreement for an all-stock transaction, combining Avere's oral IL-23 program with NextCure's public market infrastructure.

NextCure, Inc. reported a grant of 8,270 employee stock options to Senior VP and General Counsel Kevin G. Shaw with an exercise price of $10.85.

NextCure's Chief Medical Officer, Udayan Guha, was granted 14,670 employee stock options with an exercise price of $10.85.

NextCure, Inc. Senior Vice President Sourav Kundu was granted 8,270 employee stock options with an exercise price of $10.85.

NextCure, Inc. Chief Operating Officer Timothy Mayer was granted 14,670 employee stock options with an exercise price of $10.85.

NextCure, Inc. President and CEO Michael Richman was granted 38,190 employee stock options with an exercise price of $10.85, vesting over four years.

NextCure's Chief Financial Officer, Steven P. Cobourn, was granted 14,670 employee stock options with a vesting schedule extending to 2027 and beyond.

NextCure, Inc. Director John G. Houston has acquired 18,700 stock options with an exercise price of $0.47, vesting by June 2026.

NextCure, Inc. Director Elaine V. Jones was granted 18,700 stock options with an exercise price of $0.47 per share, aligning her interests with the company's performance.

NextCure, Inc. Director David S. Kabakoff was granted 28,050 stock options with an exercise price of $0.47, vesting by June 2026.

NextCure, Inc. Director Anne Elizabeth Borgman has acquired 18,700 stock options with an exercise price of $0.47, vesting by June 2026.

NextCure, Inc. Director Stephen W. Webster was granted 18,700 stock options with an exercise price of $0.47, vesting by June 2026.

NextCure, Inc. Director Ellen Feigal reported the acquisition of 18,700 stock options with an exercise price of $0.47, vesting by June 2026.

NextCure's Senior Vice President and General Counsel, Kevin G. Shaw, acquired 66,125 stock options on January 31, 2025.

NextCure's Chief Operating Officer, Timothy Mayer, was granted stock options for 117,375 shares of common stock.

NextCure's Chief Scientific Officer, Sol Langermann, was granted 117,375 stock options at an exercise price of $0.8048 on January 31, 2025.

NextCure's Senior VP of Development and Manufacturing, Sourav Kundu, was granted 66,125 stock options on January 31, 2025.

NextCure's Chief Financial Officer, Steven P. Cobourn, has been granted 117,375 employee stock options.

NextCure's CEO, Michael Richman, was granted 305,500 stock options with a strike price of $0.8048, vesting over a four-year period.

Director Stephen W. Webster acquired 18,700 stock options in NextCure, Inc. on June 20, 2024.

Director David S. Kabakoff acquired stock options in NextCure, Inc. on June 20, 2024.

Director Elaine V. Jones acquired stock options in NextCure, Inc. on June 20, 2024.

Director John G. Houston acquired 18,700 stock options in NextCure, Inc. on June 20, 2024.

Director Ellen Feigal acquired stock options in NextCure, Inc. on June 20, 2024.